Vanda Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $215.7M+8.5% YoYTTM through 30 Jun 2026
Net Income -$274.9MTTM through 30 Jun 2026
Free Cash Flow -$143MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 94.0% |
| EBITDA Margin | -85.8% |
| Operating Margin | -69.9% |
| Net Margin | -127.4% |
Returns
-62.1%ROE
-45.1%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.61x
Net Debt-$263.8Mnet cash position
Cash & Equivalents$55.9M
Quality Metrics
Altman Z-Score-1.40
Piotroski F-Score2 / 9
FCF Margin-66.3%
Rule of 40-44.8
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $216.1M
Diluted EPS-$4.64TTMFY2025: $-3.74
Dividend
No dividend
Capital Allocation
R&D Spend$117M
Capex Intensity0.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Fanapt | $117.3M | +24.4% | View detailsExpected to continue strong growth momentum following the FDA approval for bipolar I disorder in April 2024. |
| Hetlioz | $71.4M | -6.9% | View detailsFacing ongoing pressure from generic competition in the U.S. market. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.